Does the media prefer MNKD or VNDA?

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than MannKind. MarketBeat recorded 6 mentions for Vanda Pharmaceuticals and 5 mentions for MannKind. Vanda Pharmaceuticals' average media sentiment score of 0.74 beat MannKind's score of 0.55 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OPK or VNDA?

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than OPKO Health. MarketBeat recorded 6 mentions for Vanda Pharmaceuticals and 5 mentions for OPKO Health. Vanda Pharmaceuticals' average media sentiment score of 0.74 beat OPKO Health's score of -0.03 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Vanda Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LXRX or VNDA?

In the previous week, Vanda Pharmaceuticals had 4 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 6 mentions for Vanda Pharmaceuticals and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.28 beat Vanda Pharmaceuticals' score of 0.74 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GERN or VNDA?

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than Geron. MarketBeat recorded 6 mentions for Vanda Pharmaceuticals and 5 mentions for Geron. Geron's average media sentiment score of 0.75 beat Vanda Pharmaceuticals' score of 0.74 indicating that Geron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RIGL or VNDA?

In the previous week, Vanda Pharmaceuticals had 3 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 6 mentions for Vanda Pharmaceuticals and 3 mentions for Rigel Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.74 beat Rigel Pharmaceuticals' score of 0.62 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vanda Pharmaceuticals (VNDA) Competitors

$6.00 -0.24 (-3.85%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$6.06 +0.07 (+1.08%)

As of 04:30 AM Eastern

Compare

VNDA vs. MNKD, OPK, LXRX, GERN, and RIGL

Should you buy Vanda Pharmaceuticals stock or one of its competitors? MarketBeat compares Vanda Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vanda Pharmaceuticals include MannKind (MNKD), OPKO Health (OPK), Lexicon Pharmaceuticals (LXRX), Geron (GERN), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry.

How does Vanda Pharmaceuticals compare to MannKind?

MannKind (NASDAQ:MNKD) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

MannKind has a net margin of -6.63% compared to Vanda Pharmaceuticals' net margin of -109.99%. MannKind's return on equity of -11.21% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%

MannKind has higher revenue and earnings than Vanda Pharmaceuticals. MannKind is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.58	$5.86M	-$0.07	N/A
Vanda Pharmaceuticals	$216.10M	1.67	-$220.47M	-$4.05	N/A

MannKind has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

MannKind currently has a consensus price target of $8.97, suggesting a potential upside of 122.00%. Vanda Pharmaceuticals has a consensus price target of $14.30, suggesting a potential upside of 138.33%. Given Vanda Pharmaceuticals' higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

49.6% of MannKind shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 2.6% of MannKind shares are held by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than MannKind. MarketBeat recorded 6 mentions for Vanda Pharmaceuticals and 5 mentions for MannKind. Vanda Pharmaceuticals' average media sentiment score of 0.74 beat MannKind's score of 0.55 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vanda Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MannKind beats Vanda Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to OPKO Health?

OPKO Health (NASDAQ:OPK) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than OPKO Health. MarketBeat recorded 6 mentions for Vanda Pharmaceuticals and 5 mentions for OPKO Health. Vanda Pharmaceuticals' average media sentiment score of 0.74 beat OPKO Health's score of -0.03 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Vanda Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OPKO Health has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Vanda Pharmaceuticals has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.53	-$225.68M	-$0.27	N/A
Vanda Pharmaceuticals	$216.10M	1.67	-$220.47M	-$4.05	N/A

OPKO Health has a net margin of -36.63% compared to Vanda Pharmaceuticals' net margin of -109.99%. OPKO Health's return on equity of -16.78% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%

OPKO Health currently has a consensus target price of $1.55, suggesting a potential upside of 26.02%. Vanda Pharmaceuticals has a consensus target price of $14.30, suggesting a potential upside of 138.33%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Vanda Pharmaceuticals beats OPKO Health on 9 of the 16 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Lexicon Pharmaceuticals has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Lexicon Pharmaceuticals has a net margin of -37.46% compared to Vanda Pharmaceuticals' net margin of -109.99%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%

Lexicon Pharmaceuticals has higher earnings, but lower revenue than Vanda Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	19.36	-$50.34M	-$0.07	N/A
Vanda Pharmaceuticals	$216.10M	1.67	-$220.47M	-$4.05	N/A

In the previous week, Vanda Pharmaceuticals had 4 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 6 mentions for Vanda Pharmaceuticals and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.28 beat Vanda Pharmaceuticals' score of 0.74 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vanda Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lexicon Pharmaceuticals currently has a consensus price target of $4.55, suggesting a potential upside of 109.68%. Vanda Pharmaceuticals has a consensus price target of $14.30, suggesting a potential upside of 138.33%. Given Vanda Pharmaceuticals' higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Lexicon Pharmaceuticals beats Vanda Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Geron?

Geron (NASDAQ:GERN) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than Geron. MarketBeat recorded 6 mentions for Vanda Pharmaceuticals and 5 mentions for Geron. Geron's average media sentiment score of 0.75 beat Vanda Pharmaceuticals' score of 0.74 indicating that Geron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vanda Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Geron has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Geron has higher earnings, but lower revenue than Vanda Pharmaceuticals. Geron is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$196.12M	4.65	-$83.50M	-$0.11	N/A
Vanda Pharmaceuticals	$216.10M	1.67	-$220.47M	-$4.05	N/A

Geron has a net margin of -35.48% compared to Vanda Pharmaceuticals' net margin of -109.99%. Geron's return on equity of -23.31% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%

Geron presently has a consensus target price of $4.00, suggesting a potential upside of 181.69%. Vanda Pharmaceuticals has a consensus target price of $14.30, suggesting a potential upside of 138.33%. Given Geron's higher possible upside, equities analysts plainly believe Geron is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

73.7% of Geron shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 1.7% of Geron shares are held by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Geron beats Vanda Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Vanda Pharmaceuticals compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Rigel Pharmaceuticals has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

In the previous week, Vanda Pharmaceuticals had 3 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 6 mentions for Vanda Pharmaceuticals and 3 mentions for Rigel Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.74 beat Rigel Pharmaceuticals' score of 0.62 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vanda Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Rigel Pharmaceuticals presently has a consensus price target of $54.50, suggesting a potential upside of 31.96%. Vanda Pharmaceuticals has a consensus price target of $14.30, suggesting a potential upside of 138.33%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Rigel Pharmaceuticals has higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.60	$367.02M	$18.72	2.21
Vanda Pharmaceuticals	$216.10M	1.67	-$220.47M	-$4.05	N/A

Rigel Pharmaceuticals has a net margin of 121.50% compared to Vanda Pharmaceuticals' net margin of -109.99%. Rigel Pharmaceuticals' return on equity of 47.99% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%

Summary

Rigel Pharmaceuticals beats Vanda Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Vanda Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VNDA vs. The Competition

Export

Metric	Vanda Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$375.24M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-1.48	20.85	27.11	24.26
Price / Sales	1.67	314.01	589.14	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	1.08	8.49	10.75	6.29
Net Income	-$220.47M	$23.83M	$3.58B	$330.66M
7 Day Performance	-6.10%	-3.56%	-2.10%	-1.35%
1 Month Performance	2.21%	6.31%	3.29%	-0.64%
1 Year Performance	20.72%	48.30%	26.32%	19.08%

Vanda Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VNDA Vanda Pharmaceuticals	2.3647 of 5 stars	$6.00 -3.8%	$14.30 +138.3%	+26.6%	$375.24M	$216.10M	N/A	290
MNKD MannKind	3.5999 of 5 stars	$4.27 -5.5%	$8.97 +110.0%	+7.2%	$1.32B	$348.97M	N/A	400
OPK OPKO Health	2.1042 of 5 stars	$1.50 -1.3%	$1.55 +3.3%	-8.9%	$1.13B	$606.90M	N/A	1,373	News Coverage Analyst Revision
LXRX Lexicon Pharmaceuticals	2.2265 of 5 stars	$2.32 flat	$4.55 +96.1%	+100.9%	$1.03B	$69.64M	N/A	140	Positive News
GERN Geron	1.8249 of 5 stars	$1.44 +5.9%	$2.50 +73.6%	+7.6%	$923.79M	$183.88M	N/A	70	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VNDA) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. MNKD, OPK, LXRX, GERN, and RIGL

How does Vanda Pharmaceuticals compare to MannKind?

Summary

How does Vanda Pharmaceuticals compare to OPKO Health?

Summary

How does Vanda Pharmaceuticals compare to Lexicon Pharmaceuticals?

Summary

How does Vanda Pharmaceuticals compare to Geron?

Summary

How does Vanda Pharmaceuticals compare to Rigel Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vanda Pharmaceuticals (VNDA) Competitors

VNDA vs. MNKD, OPK, LXRX, GERN, and RIGL

How does Vanda Pharmaceuticals compare to MannKind?

Is MNKD or VNDA more profitable?

Which has higher earnings & valuation, MNKD or VNDA?

Which has more risk and volatility, MNKD or VNDA?

Do analysts prefer MNKD or VNDA?

Do institutionals & insiders have more ownership in MNKD or VNDA?

Does the media prefer MNKD or VNDA?

Summary

How does Vanda Pharmaceuticals compare to OPKO Health?

Does the media prefer OPK or VNDA?

Which has more risk and volatility, OPK or VNDA?

Which has preferable valuation and earnings, OPK or VNDA?

Is OPK or VNDA more profitable?

Do analysts recommend OPK or VNDA?

Do institutionals and insiders have more ownership in OPK or VNDA?

Summary

How does Vanda Pharmaceuticals compare to Lexicon Pharmaceuticals?

Which has more volatility and risk, LXRX or VNDA?

Is LXRX or VNDA more profitable?

Which has stronger earnings & valuation, LXRX or VNDA?

Does the media prefer LXRX or VNDA?

Do institutionals & insiders have more ownership in LXRX or VNDA?

Do analysts recommend LXRX or VNDA?

Summary

How does Vanda Pharmaceuticals compare to Geron?

Does the media prefer GERN or VNDA?

Which has more volatility & risk, GERN or VNDA?

Which has higher earnings and valuation, GERN or VNDA?

Is GERN or VNDA more profitable?

Do analysts rate GERN or VNDA?

Do institutionals & insiders hold more shares of GERN or VNDA?

Summary

How does Vanda Pharmaceuticals compare to Rigel Pharmaceuticals?

Which has more risk & volatility, RIGL or VNDA?

Does the media refer more to RIGL or VNDA?

Do institutionals and insiders have more ownership in RIGL or VNDA?

Do analysts prefer RIGL or VNDA?

Which has higher valuation & earnings, RIGL or VNDA?

Is RIGL or VNDA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA vs. The Competition

Vanda Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools